TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Nyxoah ( (NYXH) ) has issued an announcement.
On November 13, 2025, Nyxoah SA announced several financial initiatives to support its growth and expansion plans. The company entered into subscription agreements for a private placement of ordinary shares, expected to raise approximately €17.0 million, and a registered direct offering to raise about U.S.$5.6 million. Additionally, Nyxoah agreed to a notes offering with a potential total of €45.0 million in convertible notes. These funds are intended to advance the commercialization of the Genio system, support clinical research, and explore new technologies and collaborations in the field of OSA treatment.
The most recent analyst rating on (NYXH) stock is a Buy with a EUR10.50 price target. To see the full list of analyst forecasts on Nyxoah stock, see the NYXH Stock Forecast page.
More about Nyxoah
Nyxoah SA is a company operating in the medical technology industry, focusing on the development and commercialization of innovative solutions for the treatment of obstructive sleep apnea (OSA). Their primary product, the Genio system, is designed to address OSA and they are actively working on expanding their market presence, particularly in the United States and other initial target markets.
Average Trading Volume: 85,653
Current Market Cap: €181.5M
For an in-depth examination of NYXH stock, go to TipRanks’ Overview page.